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SUMMARY – Inflammatory bowel diseases are multifactorial disorders the clinical manifestation 
of which depends on the interaction among immune response, genetic and environmental factors. 
There is growing evidence that cytokines and gene polymorphisms have an important role in disease 
pathogenesis in various populations although molecular mechanism of their signaling and interactions 
is not fully understood yet. The present study aimed at exploring the effects of interleukin-6, C-reac-
tive protein and interleukin-6 rs1800795 polymorphism on the development of Crohn’s disease, ulcer-
ative colitis and inflammatory bowel diseases overall and at determining differences between inflam-
matory bowel disease patients and healthy controls. A total of 132 inflammatory bowel disease pa-
tients and 71 healthy blood donors were investigated. In order to assess the clinical relevance of inter-
leukin-6 and C-reactive protein serum concentration and interleukin-6 rs1800795 single nucleotide 
polymorphism in patients with Crohn’s disease and ulcerative colitis, we performed a cross-sectional, 
case-control study. Quantitative assessment of serum interleukin-6 and C-reactive protein was per-
formed with solid-phase, enzyme-labeled, chemiluminescent sequential immunometric and immuno-
turbidimetric assay, respectively. A real-time fluorescence resonance energy transfer-based method on 
a LightCyclerTM PCR 1.2 was used for genotyping of IL-6 rs1800795 polymorphism. Both inter-
leukin-6 and C-reactive protein serum levels were elevated in Crohn’s disease and ulcerative colitis 
patients. Positive correlations were observed between C-reactive protein and interleukin-6 serum con-
centration and ulcerative colitis activity index as measured by modified Truelove-Witt’s severity index 
scale. C-reactive protein serum level was higher in Crohn’s disease patients without intestinal resec-
tion than in Crohn’s disease patients with prior intestinal resection. In ulcerative colitis patients, inter-
leukin-6 and C-reactive protein serum levels were statistically significantly higher in CC interleu-
kin-6 genotype in comparison to GG+GC genotype. Analysis of the promoter region of the interleu-
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kin-6 rs1800795 gene polymorphism showed no statistically significant difference in allele frequency 
either between inflammatory bowel disease patients and healthy controls or between the two inflam-
matory bowel disease phenotypes and healthy controls. Associations presented in this study give a 
potentially important insight into the role of interleukin-6 and C-reactive protein signaling and inter-
leukin-6 polymorphism in the pathogenesis of Crohn’s disease and ulcerative colitis disease.
Key words: Crohn’s disease; Colitis, ulcerative; Interleukin-6; C-reactive protein; Polymorphism, single 
nucleotide; Inflammatory bowel diseases
Introduction
Inflammatory bowel diseases (IBD) comprise a 
large spectrum of clinical presentations, the major 
phenotypes being Crohn’s disease (CD) and ulcerative 
colitis (UC). These are chronic idiopathic inflamma-
tory disorders of the gastrointestinal tract character-
ized by variable disease course and prognosis with epi-
sodes of clinical activity as a result of active inflamma-
tion1,2. IBDs are multifactorial, polygenic diseases 
characterized by an inappropriate inflammatory re-
sponse to intestinal microbes in a genetically suscep-
tible host3. The underlying immunopathogenesis of 
IBD is not fully understood. Genetic studies high-
lighted the importance of host-microbe interactions 
with genetic factors such as nucleotide oligomeriza-
tion domain 2 (NOD2), autophagy genes and compo-
nents of the interleukin-23-type 17 helper T-cell 
(Th17) pathway playing major roles in perpetuating 
the abnormal inflammatory response in IBD3,4. We 
previously studied the effect of interleukin-23 receptor 
single nucleotide polymorphisms (SNP) on the devel-
opment of CD and UC in patients from a Croatian 
tertiary clinical center and found that certain poly-
morphisms were associated with a protective role in 
the development of IBD, which was also previously 
described in other populations5.
Interleukin 6 (IL-6), together with other cytokines 
such as interleukin 8 (IL-8), interleukin 1ß (IL-1ß) or 
tumor necrosis factor alpha (TNFα), was found to play 
a key role in the signaling mechanisms in the develop-
ment of IBD6-8. Serum IL-6 level was elevated in CD 
and UC patients and correlated positively with disease 
activity and other inflammation markers in a Croatian 
patient population, as studied by our research group7. 
Emerging specific anti IL-6 therapies might contrib-
ute to better disease control in the future9,10. Disrup-
tion of IL-6 regulation has been related to several im-
mune-mediated inflammatory diseases such as rheu-
matoid arthritis, systemic juvenile idiopathic arthritis, 
Castleman disease, various types of cancer, and IBD11. 
Baran et al. and Scheller et al. state that IL-6 cytokine 
family members have pro- and anti-inflammatory ac-
tivities that are preceded by activation of target genes 
involved in differentiation, survival, apoptosis and pro-
liferation12,13. In activated T lymphocytes at the site of 
inflammation, IL-6 activates transcription of anti-
apoptotic genes Bcl-2 and Bcl-xl via signal transducer 
and activator of transcription 3 (STAT3), enabling 
survival and clonal expansion of T lymphocytes14. 
These processes result in intensive cytokine synthesis, 
as well as in matrix metalloproteinases, thus promot-
ing chronic inflammation and tissue destruction, 
which is one of the clinical features of IBD.
C-reactive protein (CRP) is often considered as a 
nonspecific inflammatory marker but it is also an im-
munological synapse between innate and adoptive im-
munity, as well as in the interaction with IL-6, between 
pro- and anti-inflammatory activity in complex IBD 
mechanisms15. CRP expression is activated by IL-6, 
but also by IL-1β and TNFα signaling in hepato-
cytes16, with significant interindividual variations in 
basal serum concentrations. By feedback mechanism, 
CRP positively and negatively regulates IL-6 synthe-
sis, which is dependent on CRP concentration and 
FcγR macrophage isoforms17. In IBD, there are sig-
nificant but yet insufficiently known interindividual 
differences in CRP response to disease activity, includ-
ing the unexplained role of IL-6 in CRP serum con-
centrations. It is also unknown whether and to what 
extent gene variations in the IL-6 signaling pathway 
affect CRP dynamics in IBD.
Since increased secretion of the pro-inflammatory 
IL-6 seems to be important in the immunopathogen-
esis of IBD, the question arises if the functionally rel-
evant polymorphism of the promoter region of IL-6 
(G/C at position -174) is associated with IBD. The 
IL-6 G/C SNP at position -174 has been linked to 
changes in IL-6 production18,19. Baseline IL-6 release 
from macrophages is significantly lower in CC geno-
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types compared to GG genotypes, with GC individu-
als having an intermediate phenotype18. Klein et al. did 
not find an association of this polymorphism with CD 
and UC patients20, but Balding et al. found a signifi-
cant difference in the frequency of IL-6-174 geno-
types in the UC group (GG=40%, GC=41%, CC=19%) 
compared with the CD group (GG=22%, GC=64%, 
CC=14%), suggesting a potential difference in the 
pathophysiology of these two diseases6. Vickers et al., 
Wypasek et al. and Ferrari et al. state that IL-6 poly-
morphism may also be related to CRP values21-23, but 
whether and how much gene variation in IL-6 signal 
pathway affects the dynamics of CRP in IBD is still 
unknown.
The aim of the present study was to determine if 
the IL-6 -174 G/C SNP was associated with CD and 
UC patients from a Croatian tertiary center and 
whether there was difference in SNP genotype fre-
quency between CD and UC individuals. In addition, 
the study aimed at exploring the effect of IL-6 -174 
G/C SNP on CRP and IL-6 serum concentration. The 
research is relevant for gaining more insight into the 
pathogenetic mechanisms of IBD in the Croatian pa-
tient population, as well as for optimization and effi-
cient use of future individualized therapies specifically 
targeting pro-inflammatory signaling factors.
Materials and methods
Patients
A total of 50 patients with CD (26 males, median 
age 35 yrs, interquartile range 30-45 yrs), and 93 pa-
tients with UC (52 males, median age 36 yrs, inter-
quartile range 26-47 yrs), and 71 ethnically and geo-
graphically matched healthy control subjects (median 
age 36 yrs, interquartile range 26-47 yrs) were included 
in the study. All were adults, Caucasian and living in 
eastern Croatia. Diagnosis of IBD (CD or UC) was 
established according to standard clinical criteria, in-
cluding endoscopic, radiological and histopathologic 
analysis at the Osijek University Hospital Centre, 
Osijek, Croatia. Clinical activity of CD and UC was 
evaluated using the Crohn’s disease activity index 
(CDAI) and modified Truelove-Witt’s severity index 
(MTWSI), respectively. Subjects with infective and 
nonspecific colitis, multiple sclerosis, confirmed auto-
immune or malignant diseases were excluded from the 
study. There were 29 patients under treatment with 
corticosteroids. They received either methylpredniso-
lone (2 CD patients, median dose 16 mg/daily, range 
8-40 mg; n=10) or prednisone (9 CD patients, median 
dose 17.5, range 5-40 mg, n=12). Median follow-up 
for the entire cohort of IBD patients was 6 (interquar-
tile range 3-12) years. The institutional Ethics Com-
mittee approved the study (reference number: 602-
04/17-08/12, reg. no.: 2158-61-07-17-217). A written 
informed consent was obtained from each patient.
SNP determination – real-time PCR assay  
for interleukin-6 promoter (-174G → C) genotyping
Genomic DNA was extracted from 200 μL EDTA 
blood with a DNA isolation kit (High Pure PCR 
Template Preparation Kit, Roche Diagnostics, Mann-
heim, Germany) according to the manufacturer’s in-
structions. Primers were obtained from TIBMOLBI-
OL (Berlin, Germany) and kit for PCR (LightCycler 
FastStart DNA Master SYBR Green Kit) was pur-
chased from Roche Diagnostics, Mannheim, Germa-
ny. Genotyping was carried out using primers and 
fluorescent labeled probes in a LightCycler System 
(Roche Diagnostics, Mannheim, Germany) with sub-
sequent fluorescent probe melting point analysis24. A 
master mix contained 2.25 mM MgCl2, 0.5 μM of the 
primers 5´- TTA CTC TTT GTC AAG ACA TGC 
CA - 3´ and 5´- ATG AGC CTC AGA CAT CTC 
CAG - 3´, and 0.2 μM of the probes: 5´- CTA AGC 
TGC ACT TTT CCC CCT AGT --FL and LC640- 
GTG TCT TGCGAT GCT AAA GGA --PH, and 
2 μL of FastStart (Roche Diagnostics, Mannheim, 
Germany) mixture. The 175 bp PCR product obtained 
was analyzed using melting curve analysis (mutant ho-
mozygote IL6 -174C/C - 57.0 °C; heterozygote IL6 
-174G/C - 57.0 °C and 64.0; wild type homozygote 
IL6 -174G/G - 64.0 °C).
IL-6 serum level determination
Blood samples were obtained by venipuncture in 
the morning when the subjects were fasting. Blood 
was drawn from cubital vein of each patient into a tube 
without clot promoting additives (Becton Dickinson 
Vacutainers Systems, Belliver Industrial Estate, Plym-
outh, UK). After resting for 30 minutes in upright po-
sition, samples were centrifuged for 10 minutes at 
3,000 rpm (Hettich Rotina 380 R, Tuttlingen, Ger-
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many). Sera were separated from cells and stored at 
-20 °C until analysis.
Quantitative assessment of IL-6 serum concentra-
tion was performed with solid-phase, enzyme-labeled, 
chemiluminescent sequential immunometric assay on 
a Siemens Immulite 1000 (Siemens Healthcare Diag-
nostics, Llanberis, Gwynedd, UK) in incubation cycles 
of 2x30 minutes according to the manufacturer’s in-
structions.
Commercial Immulite IL-6 kit (Siemens Health-
care Diagnostics, Llanberis, Gwynedd, UK) contained 
test units coated with a monoclonal murine anti-IL-6 
antibody, and two IL-6 reagent wedges containing 7.5 
mL of a protein/buffer matrix and 7.5 mL of alkaline 
phosphatase conjugated to polyclonal sheep anti-IL-6 
antibody in buffer, respectively, as well as IL-6 low and 
high adjustors of lyophilized IL-6 in a protein buffer 
matrix. IL-6 assay was calibrated with low and high 
adjustors, both reconstituted with 3 mL distilled water 
and run in tetraplicates. As an aid in monitoring per-
formance of assays, two controls (Siemens Healthcare 
Diagnostics, Llanberis, Gwynedd, UK) containing dif-
ferent concentrations of IL-6 lyophilized cytokines in 
a human serum matrix were used. Both were reconsti-
tuted with 5 mL distilled water within 30 minutes 
prior to use and were assayed in duplicates in the same 
manner as patient samples.
CRP serum level determination
Blood samples were obtained by venipuncture in 
the morning when the subjects were fasting. Blood 
was drawn from cubital vein of each patient into a tube 
without clot promoting additives (Becton Dickinson, 
New Jersey, USA). After resting for 30 minutes in up-
right position, samples were centrifuged for 10 min-
utes at 3,000 rpm (Hettich Rotina 380 R, Tuttlingen, 
Germany). Sera were separated from cells and stored 
at 2-8 °C until analysis. To determine CRP serum 
concentration, a commercial CRP Latex reagent was 
used (Beckman Coulter, Brea, CA, USA) on a Beck-
man Coulter AU680 analyzer according to the manu-
facturer’s instructions. To calibrate reagents, Beckman 
Coulter CRP Latex Calibrator Normal Set was used 
(cat. no. ODC0026). CRP calibrator values are trace-
able to CRM 47025 of the International Federation of 
Clinical Chemistry (IFCC). For quality control, com-
mercial control samples at two concentration levels 
were used, as follows: Seronorm Immunoprotein Lyo-
L1 cat. no. 202805 and Seronorm Immunoprotein 
Lyo-L2 cat. No. 202905 (Sero, Bilinstad, Norway). 
The test principle is based on the turbidity measure-
ment of the reaction solution (immune turbidimetry). 
After mixing the test sample with the reagent, CRP 
from the sample specifically binds to the anti-CRP 
antibodies on reagent latex particles, thereby produc-
ing insoluble aggregates and increasing turbidity of the 
reaction mixture. The increase in turbidity is propor-
tional to CRP concentration in the sample.
Statistical methods and analysis
Differences between groups were tested using 
Mann-Whitney or Kruskal-Wallis test with Bonferro-
ni-Dunn post hoc procedure. Fisher exact test and χ2-
test were used for categorical variables. To test devia-
tions from Hardy-Weinberg equilibrium, Guo-
Thompson exact test was used26, and to describe allelic 
association D’ coefficient was used (PLINK 1.07 pro-
gram)27-29.
For individual polymorphisms, statistical signifi-
cance was simultaneously tested by Westfall-Young 
permutations (104 randomizations)30 and empirical p-
values corrected for multiple testing were obtained 
(maxT, PLINK 1.07). The statistical power of alleles 
and genotype associations was estimated using the 
Genetic Power Calculator program31. If not otherwise 
specified, statistical analysis was conducted using 
SPSS 20.0 (SPSS Inc., Chicago, IL, USA). Two-tailed 




Serum level of IL-6 (pg/mL) was assessed in 32 
CD, 68 UC and 71 control group subjects. In both pa-
tient groups, IL-6 was significantly higher when com-
pared to the control group, but there was no significant 
difference in IL-6 serum levels between CD and UC 
groups (Kruskal-Wallis test) (Table 1). There was no 
statistically significant difference between patients re-
ceiving corticosteroid therapy (n=21, confidence inter-
val (CI)=3.5, interquartile range (IQR)=2.675-14.15) 
and those not receiving this therapy (n=79, CI=2.31, 
IQR=1.99 -6.38, U=604, p=0.50; Mann Whitney).
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The difference in IL-6 levels between CD patients 
with prior intestinal resection (n=8, median=2.61, 
IQR=2.02-3.75) and those with no previous resection 
(n=24, median=3.55, IQR=1.99-7.23) was not statisti-
cally significant (U=72, p=0.313, Mann Whitney).
The difference in IL-6 levels between patients with 
inactive CD (CDAI <150, n=17, CI=1.99, IQR=1.99-
3.77) and healthy controls (n=71, CI=1.99, IQR=1.99-
1.99) was statistically significant (U=362, p<0.001, 
Mann-Whitney).
In both CD and UC patients, there was a strong 
positive correlation between IL-6 and CRP levels 
(ρ=0.68, p<0.01 and r=0.78, p<0.01, respectively).
Serum IL-6 levels correlated statistically signifi-
cantly with CDAI in CD patients (ρ=0.48, p<0.01) 
and with MTWSI in UC patients (ρ=0.66, p<0.01).
CRP
C-reactive protein levels were obtained in 132 IBD 
patients (84 UC) but not in healthy controls. CRP 
 levels in both CD and UC patients were higher than 
reference intervals (<5.0 mg/L). There were no statisti-
cally significant differences in CRP levels in IBD pa-
tients between those receiving corticosteroid therapy 
and those not receiving it (p=0.777, Kruskal-Wallis 
test). In IBD patients, there was a strong correlation 
between CRP and IL-6 levels (ρ=0.756, p<0.001), as 
well as between CRP and MTWSI (ρ=0.586, p<0.001). 
The correlation between CRP and CDAI was not sta-
tistically significant (ρ=0.208, p=0.166).
Difference in CRP levels between CD (n=48, 
CI=9.35, IQR=2.2-39.02) and UC patients (n=84, 
CI=6.75, IQR=2.03-51.63) was not statistically sig-
nificant (U=1984.5, p=0.882, Mann-Whitney).
There was a statistically significant difference in 
CRP levels between CD patients with prior intestinal 
resection (n=11, CI=2.2, IQR=0.9-4.5) and those with 
no previous resection (n=37, CI=10.3, IQR=6.05-
46.75, U=88, p=0.005, Mann Whitney).
IL-6 rs1800795 polymorphism
Analysis of IL-6 rs1800795 polymorphism showed 
that the genotype distribution was in Hardy-Weinberg 
equilibrium (Table 2).
In order to investigate the role of IL-6 genotype in 
IL-6 serum levels and CRP acute phase protein levels, 
analysis of rs1800795 polymorphism in IL-6 gene was 
conducted. Patients were categorized by IBD type and 
IL-6 genotype. Genotyping was carried out in 32 CD 
and 65 UC patients. Genotype distributions are shown 
in Table 3. No statistically significant difference was 
observed in allele frequency either between IBD or 
two IBD phenotypes and healthy controls.
Association of rs1800795 and IL-6 serum level
A statistically significant difference in IL-6 levels 
was found among the three genotypes in UC patients 
(p=0.045) (Table 4). Post hoc Bonferroni-Dunn test 
showed statistically significant IL-6 levels in CC rela-
tive to GC genotype. No statistically significant differ-








Median IQR Median IQR Median IQR
IL-6 (pg/mL) <0.001‡ 3.25 1.99-5.96 2.67 1.99-11.20 1.99 1.99-1.99
IL-6 = interleukin-6; CD = Crohn’s disease; UC = ulcerative colitis; n = number of subjects, IQR = interquartile range, ‡ post hoc Dunn-
Bonferroni: K<CD (p<0.001); K<UC (p<0.001)
Table 2. Comparison of allele frequency of interleukin-6 (IL-6) single nucleotide polymorphism (SNP)  
between patients with inflammatory bowel diseases (IBD) and healthy controls






(controls) HW p 
rs1800795 C 0.419 0.391 1.12-1.75 0.973 0.613 0.425
SNP = single nucleotide polymorphism; IBD = inflammatory bowel disease patients; CI = confidence interval, HWE = Hardy-Weinberg 
equilibrium; OR = odds ratio; *empirical p-value, 104 permutation, Westfall-Young correction, †Guo-Thompson exact test
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Table 5. Comparison of interleukin-6 (IL-6) serum levels between GG+GC  
and CC genotypes
SNP
IL-6 (pg/mL) GG+GC n CC n p
IBD 2.46 (1.99-6.44) 81 4.62 (2.79-9.36) 16 0.052
UC 2.31 (1.99-8.94) 57 7.17 (3,12-36.85) 8 0.02
CD 3.16 (1.99-4.68) 24 3.77 (2.24-8.03) 8 0.683
Data are presented as median with interquartile range, Mann-Whitney U test; n = number of cases; CD = 
Crohn’s disease patients; UC = ulcerative colitis patients; IBD = inflammatory bowel disease patients; SNP = 
single nucleotide polymorphism
Table 4. Comparison of IL-6 among genotypes (GG, GC and CC) by disease (Kruskal-Wallis
Genotype
















CD = Crohn’s disease patients; UC = ulcerative colitis patients; IBD = inflammatory bowel disease patients; n = number of cases; †Kruskal-
Wallis test; ‡post hoc Dunn-Bonferroni (z): GC<CC (p=0.032)
Table 3. Comparison of IL-6 rs1800795 genotype and allele frequency between inflammatory bowel disease patients 
and healthy controls
Genotype association
IL-6 (rs1800795) Genotype IBDn (%)
Controls
n (%) p* OR (95% CI)
IBD CC 16 (16.2) 9 (13) 0.976 1.33 (0.5-3.65)§
GC 51 (51.5) 36 (52.2) 1.06 (0.53-2.1)
GG 32 (32.3) 24 (34.8) Ref
CD CC 8 (25) 9 (13) 0.145 2.37 (0.67-8.24)
GC 15 (46.9) 36 (52.2) 1.11 (0.42-3.05)
GG 9 (28.1) 24 (34.8) Ref
UC CC 8 (11.9) 9 (13) 0.846 0.93 (0.3-2.89)
GC 36 (53.7) 36 (52.2) 1.04 (0.5-2.19)
GG 23 (34.4) 24 (34.8) Ref
Allele associations
Phenotype Allele Frequency (IBD)
Frequency 
(controls) OR (95% CI) p*
CD C 0.484 0.391 1.46 (0.8-2.65) 0.651
UC C 0.388 0.391 0.99 (0.59-1.66) Ref
IL-6 = interleukin 6; IBD = inflammatory bowel disease patients; CD = Crohn’s disease patients; CI = confidence interval; OR = odds ratio; 
Ref = reference genotype; UC = ulcerative colitis patients; *empirical p-value; 104 permutation, Westfall-Young correction
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ences in IL-6 levels were found among the three geno-
types in CD patients and IBD patients overall.
Next, GG and GC alleles were joined into one cat-
egory and its IL-6 level was compared with that of the 
CC genotype, by disease (UC and CD) and UBC (UC 
and CD combined) (Table 5). IL-6 level in the 
GG+GC allele (median=2.31, IQR=1.99-8.94) was 
statistically significantly lower than in the CC allele 
(median=7.17, IQR=3.12-36.85) in UC patients 
(U=341, p=0.02, Mann-Whitney), as well as in IBD 
patients. In CD patients and in IBD patients overall, 
there was no statistically significant difference in IL-6 
levels between GG+GC and CC genotypes (U=114, 
p=0.454 and U=863, p=0.032, respectively).
Association between rs1800795 and CRP serum level
No statistically significant differences were found in 
CRP levels among the three IL-6 genotypes (Table 6).
In UC patients, CRP levels were statistically sig-
nificantly lower in GG+GC than in CC genotype 
(U=323.5, p=0.017). In IBD (U=692.5, p=0.19) and 
CD patients (U=70.5, p=0.631), difference in CRP 
levels was not statistically significant between the gen-
otypes (Table 7).
Discussion
Inflammatory bowel diseases are chronic inflamma-
tory intestinal disorders often followed by unpredictable 
relapsing-remitting course32,33. The IBD pathophysiol-
ogy is not completely understood yet and therefore 
therapeutic strategies are far from ideal34. The disease 
pathogenesis includes immune, genetic, environmental 
and microbial factors, which are the focus of intensive 
studies conducted with the aim to generate new insights 
and advances in diagnostics and treatment35.
Our results pointed to a statistically significant dif-
ference in IL-6 serum level between IBD patients and 
healthy control subjects, with no significant difference 
between CD and UC patients in CRP and IL-6 serum 
levels. CRP level in IBD patients was significantly 
higher than the CRP reference interval (<5.0 mg/L), 
with a positive correlation with IL-6 serum levels. 
Solem et al., Poullis et al. and Yang et al. also found 
higher CRP serum levels in CD and UC patients, with 
a positive correlation with IL-6 serum levels36-38, 
whereas in the study by Fagan et al., CRP was signifi-
cantly higher in UC than in CD patients39. Similar to 
our results, Beck and Wallace, Seegert et al. and Yoshi-
Table 7. Comparison of C-reactive protein (CRP) levels between GG+GC and CC genotypes
SNP
CRP GG+GC n CC n p
IBD 7.40 (2.00-23.25) 76 8.70 (4.30-167.40) 15 0.963
UC 6.00 (2.00-22.70) 53 90.20 (6.03-293.23) 8 0.022
CB 8.20 (1.10-40.70) 23 5.90 (1.70-16.30) 7 0.624
Data are presented as median with interquartile range; Mann-Whitney U test; CD = Crohn’s disease patients; 
UC = ulcerative colitis patients; IBD = inflammatory bowel disease patients; SNP = single nucleotide poly-
morphism; n= number of cases
Table 6. Comparison of C-reactive protein levels (CRP) between IL-6 genotypes (GG, GC and CC) in IBD,  
UC and CD patients (Kruskal-Wallis test)
SNP
















CD = Crohn’s disease patients; UC = ulcerative colitis patients; IBD = inflammatory bowel disease patients; SNP = single nucleotide poly-
morphism; n = number of cases
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moto et al. also report elevated IL-6 levels in both IBD 
phenotypes40-42. Rogler et al. and Feng et al. defined 
IBD as proinflammatory and anti-inflammatory cyto-
kine imbalance with elevated IL-6, TNF, IL-8 and 
IL-1243,44. In contrast to our results, Korolkova et al. 
and Mahida et al. report elevated IL-6 serum levels in 
patients with active CD but not in patients with 
UC45,46.
Interleukin-6 released from macrophages by TLR/
NOD2 cascades is the main cytokine which induces 
acute phase CRP, serum amyloid A, haptoglobin and 
fibrinogen proteins47-49. Newly synthesized CRP in-
duces shedding of neutrophils mIL-6R, which are the 
first cells to arrive at the site of intestinal epithelial 
barrier damage and mediate IL-6 trans-signaling50,51. 
The IL-6 - sIL-6Rα interactions stabilize the complex 
and therefore increase IL-6 half-life and bioavailabil-
ity by 50%52. Consequently, IL-6 trans-signaling in 
activated T lymphocytes activates anti-apoptotic Bcl-
2 and Bcl-xl genes, which enables accumulation, sur-
vival and antigen-specific T cell expansion53,54. Mit-
suyama et al., Scheller et al. and Kishimoto demon-
strated that, in addition to IL-6, serum level of soluble 
IL-6Rα (sIL-6Rα) was elevated too55-57. Jones et al. 
found elevated CRP and IL-6 serum levels in IBD pa-
tients and a positive correlation between endoscopic 
but not clinical disease activity58. Florin et al. report on 
elevated CRP levels in CD patients but also on active 
CD patients with persistently low CRP values59. This 
phenomenon could indicate lower BMI and stenosing 
versus penetrating CD. We found a positive relation-
ship between IL-6 serum level and disease activity in-
dex according to MTWSI/CDAI scale in both IBD 
phenotypes, and a positive CRP correlation with 
MTWSI but not with CDAI. IL-6 serum levels were 
statistically significantly higher in patients with active 
CD (CDAI >150) and severe UC (MTWSI >6) than 
in inactive CD (CDAI <150) and mild UC (MTWSI 
<4) patients. Similar to our results, Hyams et al. and 
Reinisch et al. report on higher IL-6 serum level in 
IBD patients with positive correlation with disease in-
flammatory activity60,61. Brown et al. found that IL-6 
serum levels correlated more significantly with UC 
than CD disease activity62. Contrary to our research, 
Gross et al. could not confirm the relationship between 
IL-6 serum levels and disease activity63. However, in 
vivo animal studies support the role of IL-6 in disease 
severity, i.e. adoptive transfer CD4+CD45RBhigh T cells 
IL-6-/- donors in severe combined immunodeficiency 
(SCID) model resulted in milder inflammatory colon 
disease64. Next, statistically significantly higher IL-6 
levels were observed in patients with inactive disease 
than in healthy controls. As the synthesis of many cy-
tokines is coactivated by the same transcriptional fac-
tors such as NFκB and AP-1, which bind to cis regula-
tory elements within the gene promoter region, similar 
stimuli often lead to co-activation of primordial cyto-
kine expression such as IL-6, TNFα and IL-1β65-67. In 
their study of IL-6 mRNA in IBD patient and healthy 
control colon samples, Stevens et al. found elevated 
IL-6 transcript only in active CD and UC68.
Additional studies are needed to illuminate the 
contributions of different cellular and tissue sources of 
IL-6 to its serum level and dynamics. In this context, 
elevated IL-6 serum level in patients with inactive dis-
ease leads to many hypotheses about its origin, from 
residual subclinical inflammation to the role of intesti-
nal flora and the process of tissue injury healing. Con-
cerning the latter, in addition to inflammatory signal-
ing, IL-6 has a role in the processes of intestinal epi-
thelial regeneration, and thus inflammatory stimuli 
reduction. This is reinforced by cases of disease aggra-
vation after tocilizumab administration, as first de-
scribed by Atreya et al. and Shetty et al.69,70.
Increased IL-6 and CRP levels in patients with in-
active CD found in our study may indicate activation 
of the mucus immune system or increased intestinal 
permeability. All of these stimuli can activate IL-6 and 
CRP synthesis in patients with inactive CD but in-
creased IL-6 production may also be attributed to the 
potential existence of subclinical but relevant residual 
inflammatory activity of the disease. Van Kemseke et 
al., Schreiber et al. and Wyatt et al. state that these bio-
logical abnormalities may be associated with an in-
creased risk of relapse71-73. According to Reinisch et al., 
different acute phase protein serum levels may predict 
clinical relapse but only a combination of multiple 
laboratory tests can provide a more reliable predictive 
index74. On the other hand, CRP half-life is not af-
fected by physiological or pathophysiological mecha-
nisms, resulting in decrease in its concentration in the 
period of reduced inflammatory activity, usually 19 
hours after CRP synthesis, which allows for CRP to 
be used as a therapeutic efficacy biomarker75,76. The po-
tential pathobiological role of CRP is invariable and 
unclear, and probably outweighs its role as a mere bio-
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chemical and therapeutic marker. Namely, Zouki et al. 
emphasize that CRP peptides inhibit L-selectin medi-
ated neutrophil interaction with endothelial cells 
probably by binding to CD32, which is the first step to 
neutrophil extravasation77. Lower CRP concentrations 
favor CRP association to macrophage FcγRI, FcγRIIa 
and FcγRIIIa, which leads to additional synthesis and 
release of proinflammatory IL-1, IL-6 and TNFα cy-
tokines78,79. Higher CRP concentrations, in contrast, 
favor binding to macrophage FcγRIIb, which results in 
proinflammatory cytokine suppression partially medi-
ated by IL-10+Treg cells.
Although the difference in IL-6 serum levels be-
tween CD patients with and without intestinal resec-
tion was not statistically significant, the existence of 
difference cannot be unreservedly excluded. Certain 
differences may be a consequence of therapeutic mo-
dalities but also of dual effects of IL-6 signaling. Fi-
nally, gender, smoking, fat tissue and comorbidities can 
also contribute to these differences80,81. These results 
indicate that IL-6 should be observed in a wider con-
text; in addition to its proinflammatory signaling ef-
fect, IL-6 has an anti-inflammatory and regenerative 
effect, and as such is potentially actively involved in the 
mechanisms of intestinal epithelium healing82,83.
Measurement of IL-6 serum concentration can 
therefore be useful for stratifying patients with a high 
relapse risk or stratifying disease severity. However, the 
study was partially limited by the lack of longitudinal 
IL-6 serum measurement, which, we believe, would 
give better insight into the dynamics and relapse pre-
dictive value of IL-6.
Our results indicate that IL-6 serum level reflects 
CD and UC inflammatory activity. Given the signifi-
cance of signaling in IBD, IL-6 may be considered a 
potentially significant target for cytokine specific ther-
apy. However, spatial and temporal context of inflam-
matory reaction and possible interference with anti-
inflammatory or regenerative mechanisms of IL-6 
signaling should be taken into account. In this way, the 
possible role of IL-6 in the individualized screening of 
patients for personalized biological or other therapy is 
also open. This would allow IL-6 to have a role in 
screening of patients for personalized biological or 
other therapy.
Gene variations such as SNPs can affect gene tran-
scription efficiency, mRNA half-life and protein struc-
ture, as well as protein function84. Therefore, when ge-
netic variations are related to inflammatory cytokines, 
and the inflammatory process is one of the risk factors, 
certain variations may result in a higher intensity of 
the inflammatory process and thereby increased risk of 
inflammatory tissue injuries85.
The most widely studied functional polymorphism, 
transversion -174 G/C promoter region of IL-6 gene 
(rs1800795, 7_22766645_C_G, GRCh37.p13), was 
also a subject of the present study. IL-6 gene is located 
on chromosome 7 (7p15.3), and comprises 6 exons 
and 5 introns86. It was observed that the G/C transi-
tion at position 174 of the promoter region affects 
transcription of the gene activity, resulting in changes 
in IL-6 production87,88. G allele, which some authors 
consider highly productive (GG and GC genotypes), 
is associated with enhanced IL-6 expression89, while C 
allele (CC) is considered as a low productive variant 
indicating a possible protective function90. Limited re-
sults of in vitro transfection studies support this dis-
tinction91. In this study, IBD patients and healthy con-
trols did not differ significantly in the distribution of 
rs1800795 allelic and genotype frequencies. The ob-
served frequency of mutated alleles in healthy controls 
corresponded to the expected values for European 
populations and populations of European origin92. 
There was no statistically significant difference in the 
distribution of allele frequencies between the two IBD 
phenotypes either, suggesting that the predisposition 
role of this polymorphism in IBD is neither strong nor 
differential, or that the expected effect size is smaller 
than the statistical power in the study. Although other 
functional or regulatory polymorphism in the linkage 
disequilibrium with the analyzed variant cannot be ex-
cluded, there are currently no such apparent candidates 
in the IL-6 locus. However, the investigation of the 
relationship between rs1800795 and CRP and IL-6 
serum levels in UC patients indicated statistically sig-
nificantly higher IL-6 and CRP levels in CC genotype 
carriers compared to GG+GC genotypes, especially in 
the C-allele recessive model.
A study conducted in Dublin by Balding et al. 
showed that rs1800795 was involved in inflammatory 
response and contributed to susceptibility to disease 
and phenotype in IBD patients93. A Spanish popula-
tion study by Guerreiro et al. showed that GG homo-
zygotes had a six times higher risk of CD94. However, 
Pawlik et al. report that there was no significant differ-
ence between the patients and the control group in the 
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distribution of the IL-6 genotype95. Banday et al. found 
that whereas CC variant rs1800795 did not correlate 
significantly with the prospects of the disease, it did 
correlate significantly with the prospects for long-term 
complications such as development of colorectal cancer 
as one of the consequences of long-lasting IBD96. At 
the level of gene transcription regulation, Sawczenko et 
al. report on higher IL-6 and CRP serum levels associ-
ated with GG genotype in children with CD97.
After measuring IL-6 plasma levels in 102 healthy 
subjects from the London area, plasma IL-6 levels 
were also significantly lower in C allele than in G al-
lele98. It remains unclear, however, whether this result 
is an independent effect of rs1800795, or the result of 
the synergy of more collocated, nonspecific gene vari-
ants within the same haplotype block. In addition to 
cis and trans effects on IL-6 expression99, effects of dis-
tant allelic variants are also possible100.
Results of research on the influence of genetic mu-
tations on tissue expression and cytokine serum levels 
in IBD patients are still contradictory, although the 
latest studies indicate a possible role of gene polymor-
phisms in the disease development and progression101. 
Mutations are therefore potential therapeutic and di-
agnostic markers of many diseases102. The causes of 
controversial associations remain unclear. IBDs in dif-
ferent populations may have different immunogenic 
mechanisms. From the above discussion, it is clear that 
IL-6 expression regulation exceeds simple divisions 
such as that into universal low and highly productive 
IL-6 allelic variants.
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Sažetak
INTERAKCIJA IZMEĐU INTERLEUKINA-6, C-REAKTIVNOG PROTEINA I INTERLEUKINA-6 (-174) 
G/C POLIMORFIZMA U PATOGENEZI CROHNOVE BOLESTI I ULCEROZNOG KOLITISA
B. Takač, S. Mihaljević, Lj. Glavaš-Obrovac, A. Kibel, M. Suver-Stević, S. Canecki-Varžić,  
M. Samardžija, I. Rajkovac, D. Kovač i M. Štefanić
Upalne bolesti crijeva predstavljaju multifaktorski poremećaj klinička manifestacija kojega ovisi o interakciji imunog 
odgovora te genetskih i okolišnih čimbenika. Rezultati više novijih istraživanja upućuju na ulogu citokina i polimorfizama 
gena u patogenezi bolesti u različitim populacijama, iako molekularni mehanizmi njihova singaliziranja i interakcije još nisu 
dovoljno poznati. Cilj ovoga istraživanja bio je ispitati učinke interleukina-6, C-reaktivnog proteina i interleukin-6 rs1800795 
na razvoj Crohnove bolesti, ulceroznoga kolitisa i upalnih bolesti crijeva općenito te utvrditi razlike između skupine ispita-
nika oboljelih od upalnih bolesti crijeva i kontrolne skupine ispitanika. U istraživanje je uključeno ukupno 132 oboljela od 
upalnih bolesti crijeva i 71 zdravi davatelj krvi. Serumska koncentracija interleukina-6 određena je kemiluminiscentnom 
sekvencijskom imunometričnom, a koncentracija C-reaktivnog proteina imunoturbidimetrijskom metodom. Analiza poli-
morfizma rs1800795 provodila se na uređaju LightCyclerTM PCR 1.2 u stvarnome vremenu temeljem prijenosa energije 
uslijed fluorescentne rezonancije. Serumske koncentracije interleukina-6 i C-reaktivnoga proteina bile su povišene i u obo-
ljelih od Crohnove bolesti i oboljelih od ulceroznoga kolitisa. Utvrđene su pozitivne korelacije između serumskih koncentra-
cija C-reaktivnoga proteina i interleukina-6 i indeksa aktivnosti ulceroznoga kolitisa mjerenoga prema ljestvici MTWSI. 
Serumska koncentracija C-reaktivnog proteina bila je viša u oboljelih od Crohnove bolesti bez prethodne resekcije crijeva u 
usporedbi s oboljelima od Crohnove bolesti s prethodnom resekcijom crijeva. U oboljelih od ulceroznoga kolitisa serumske 
koncentracije interleukina-6 i C-reaktivnog proteina bile su statistički značajno više kod CC genotipa interleukina-6 u 
 usporedbi s genotipom GG+GC. Analizom polimorfizma promotorske regije IL-6 rs1800795 nisu uočene razlike u učesta-
losti alela između oboljelih od Crohnove bolelsti, oboljelih od ulceroznoga kolitisa i kontrolne skupine ispitanika, ni razlike 
između kontrolne skupine ispitanika i oboljelih od upalnih bolesti crijeva općenito. Rezultati ove studije pružaju potencijalno 
važan uvid u ulogu signaliziranja interleukina-6 i C-reaktivnoga proteina te polimorfizma interleukina-6 u patogenezi Croh-
nove bolesti i ulceroznoga kolitisa.
Ključne riječi: Crohnova bolest; Kolitis, ulcerozni; Interleukin-6; C-reaktivni protein; Polimorfizam jednog nukleotida; Upalne 
bolesti crijeva
